Novel treatment approaches to cachexia and sarcopenia: Highlights from the 5th Cachexia Conference

Thomas Kung; Jochen Springer; Wolfram Doehner; Stefan D. Anker; Stephan von Haehling

doi:10.1517/13543781003724690

Novel treatment approaches to cachexia and sarcopenia: Highlights from the 5th Cachexia Conference

Thomas Kung
, Jochen Springer
, Wolfram Doehner
, Stefan D. Anker
, Stephan von Haehling

Research output: Contribution to journal › Article

50 Citations (Scopus)

Abstract

Cachexia is an illness that may occur in terminal stages of many chronic illnesses including cancer, chronic heart failure, chronic renal failure or chronic obstructive pulmonary disease. Effective treatments are urgently needed in order to improve the patients' quality of life and their survival. We report highlights from the 5th Cachexia Conference held in December 2009 in Barcelona, Spain. Novel therapeutic approaches shown here include melanocortin-4 receptor antagonists, myostatin inhibition, beta-blockers, IL-6 antagonism synthetic ghrelin and vitamin D.

Original language	English
Pages (from-to)	579-585
Number of pages	7
Journal	Expert Opinion on Investigational Drugs
Volume	19
Issue number	4
DOIs	https://doi.org/10.1517/13543781003724690
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1517/13543781003724690

Cite this

@article{304f5f3b64704d14b25169cbbe12c645,

title = "Novel treatment approaches to cachexia and sarcopenia: Highlights from the 5th Cachexia Conference",

abstract = "Cachexia is an illness that may occur in terminal stages of many chronic illnesses including cancer, chronic heart failure, chronic renal failure or chronic obstructive pulmonary disease. Effective treatments are urgently needed in order to improve the patients' quality of life and their survival. We report highlights from the 5th Cachexia Conference held in December 2009 in Barcelona, Spain. Novel therapeutic approaches shown here include melanocortin-4 receptor antagonists, myostatin inhibition, beta-blockers, IL-6 antagonism synthetic ghrelin and vitamin D.",

author = "Thomas Kung and Jochen Springer and Wolfram Doehner and Anker, \{Stefan D.\} and \{von Haehling\}, Stephan",

year = "2010",

doi = "10.1517/13543781003724690",

language = "English",

volume = "19",

pages = "579--585",

journal = "Expert Opinion on Investigational Drugs ",

issn = "1354-3784",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Novel treatment approaches to cachexia and sarcopenia: Highlights from the 5th Cachexia Conference

AU - Kung, Thomas

AU - Springer, Jochen

AU - Doehner, Wolfram

AU - Anker, Stefan D.

AU - von Haehling, Stephan

PY - 2010

Y1 - 2010

N2 - Cachexia is an illness that may occur in terminal stages of many chronic illnesses including cancer, chronic heart failure, chronic renal failure or chronic obstructive pulmonary disease. Effective treatments are urgently needed in order to improve the patients' quality of life and their survival. We report highlights from the 5th Cachexia Conference held in December 2009 in Barcelona, Spain. Novel therapeutic approaches shown here include melanocortin-4 receptor antagonists, myostatin inhibition, beta-blockers, IL-6 antagonism synthetic ghrelin and vitamin D.

AB - Cachexia is an illness that may occur in terminal stages of many chronic illnesses including cancer, chronic heart failure, chronic renal failure or chronic obstructive pulmonary disease. Effective treatments are urgently needed in order to improve the patients' quality of life and their survival. We report highlights from the 5th Cachexia Conference held in December 2009 in Barcelona, Spain. Novel therapeutic approaches shown here include melanocortin-4 receptor antagonists, myostatin inhibition, beta-blockers, IL-6 antagonism synthetic ghrelin and vitamin D.

U2 - 10.1517/13543781003724690

DO - 10.1517/13543781003724690

M3 - Article

SN - 1354-3784

VL - 19

SP - 579

EP - 585

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 4

ER -